Ransys 40 mg (Tablet)
Unit Price: ৳ 17.00 (5 x 6: ৳ 510.00)
Strip Price: ৳ 102.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Olmesartan medoxomil |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Title
- Ransys 40 mg Tablet
Categories
- Hypertension Medication
- Antihypertensive Agent
- Angiotensin-II Receptor Blocker
Description
- Ransys is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Dosage & Administration
- Dosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
Special Precautions
- No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with possible depletion of intravascular volume, Olmesartan should be initiated under close medical supervision and consideration should be given to use of a lower starting dose. Olmesartan may be administered with or without food.
Potential Drug Interactions
- No significant drug interactions were reported in studies in which Ransys was co-administered with digoxin or warfarin in healthy volunteers. The bioavailability of olmesartan was not significantly altered by the co-administration of antacids. Ransys is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes; thus, interactions with drugs that inhibit, induce, or are metabolized by those enzymes are not expected.
Contraindications
- Ransys 40 mg Tablet is contraindicated in patients who are hypersensitive to any component of this product.
Side Effects
- Ransys has been evaluated for safety in more than 3825 patients, with an incidence of adverse reactions similar to placebo. The overall frequency of adverse reactions was not dose related. The rate of withdrawals due to adverse reactions in all trials of hypertensive patients was 2.4% of patients treated with Ransys and 2.7% of control patients.
Pregnancy & Lactation
- When pregnancy is detected, discontinue this product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.
Precautions & Warnings
- As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with Ransys.
Overdose Effects
- There is no experience of overdose with Ransys. The most likely effects of Ransys overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred.
Therapeutic Class
- Angiotensin-ll receptor blocker
Storage Conditions
- Store in cool & dry place below 30°C, protect from light & moisture. Keep out of the reach of children.
Molecular Formula
- C29H30N6O6